Cargando…

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions

Fenebrutinib is a CYP3A substrate and time‐dependent inhibitor, as well as a BCRP and OATP1B transporter inhibitor in vitro. Physiologically‐based pharmacokinetic (PBPK) modeling strategies with the ultimate goal of understanding complex drug‐drug interactions (DDIs) and proposing doses for untested...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yuan, Ma, Fang, Jones, Nicholas S., Yoshida, Kenta, Chiang, Po‐Chang, Durk, Matthew R., Wright, Matthew R., Jin, Jin Yan, Chinn, Leslie W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306618/ https://www.ncbi.nlm.nih.gov/pubmed/32383787 http://dx.doi.org/10.1002/psp4.12515

Ejemplares similares

Understanding the Effect of Hydroxypropyl‐β‐Cyclodextrin on Fenebrutinib Absorption in an Itraconazole–Fenebrutinib Drug–Drug Interaction Study
por: Durk, Matthew R., et al.
Publicado: (2020)

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI
por: Jones, Nicholas S., et al.
Publicado: (2019)

Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis
por: Chan, Phyllis, et al.
Publicado: (2020)

Fenebrutinib in H(1) antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
por: Metz, Martin, et al.
Publicado: (2021)

Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model
por: Jing, Jing, et al.
Publicado: (2022)

Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
por: Wu, Fan, et al.
Publicado: (2020)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
por: Yoon, Deok Yong, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs
por: Mochizuki, Tatsuki, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
por: Liu, Hongrui, et al.
Publicado: (2021)

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
por: Rodriguez-Vera, Leyanis, et al.
Publicado: (2023)

Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological‐based pharmacokinetic modeling
por: Menzel, Karsten, et al.
Publicado: (2023)

Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
por: Jones, HM, et al.
Publicado: (2013)

Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development
por: Maharaj, A R, et al.
Publicado: (2014)

Physiologically‐Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug–Drug Interactions
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2022)

Investigation of Fenebrutinib Metabolism and Bioactivation Using MS(3) Methodology in Ion Trap LC/MS
por: Alsibaee, Aishah M., et al.
Publicado: (2023)

Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial
por: Cohen, Stanley, et al.
Publicado: (2020)

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2023)

Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin
por: Park, Min-Ho, et al.
Publicado: (2017)

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
por: Zhou, D, et al.
Publicado: (2016)

Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir
por: Stader, Felix, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
por: Hanke, Nina, et al.
Publicado: (2021)

Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
por: Ji, Tao, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
por: Berton, Mattia, et al.
Publicado: (2022)

Enantiospecific pharmacokinetics and drug–drug interactions of primaquine and blood-stage antimalarial drugs
por: Chairat, Kalayanee, et al.
Publicado: (2018)

Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
por: Min, Jee Sun, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug–Drug Interaction Between Clopidogrel and Dasabuvir
por: Shebley, M, et al.
Publicado: (2017)

Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions
por: Britz, Hannah, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models
por: Yu, Zhiheng, et al.
Publicado: (2022)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators
por: Marok, Fatima Zahra, et al.
Publicado: (2023)

Pharmacokinetic Drug–Drug Interactions and Herb–Drug Interactions
por: Choi, Min-Koo, et al.
Publicado: (2021)

A Physiologically Based Pharmacokinetic Model to Predict Potential Drug–Drug Interactions and Inform Dosing of Acumapimod, an Oral p38 MAPK Inhibitor
por: Agyemang, Alex, et al.
Publicado: (2020)

Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants
por: Salerno, Sara N., et al.
Publicado: (2020)

Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs
por: Janssen, J. M., et al.
Publicado: (2023)

Application of Physiologically‐Based Pharmacokinetic Modeling to Predict Gastric pH‐Dependent Drug–Drug Interactions for Weak Base Drugs
por: Dong, Zhongqi, et al.
Publicado: (2020)

Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?
por: Tod, M, et al.
Publicado: (2017)

Investigating Transporter‐Mediated Drug‐Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin
por: Wang, Q, et al.
Publicado: (2017)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Evaluation of the drug‐drug interaction potential of treosulfan using a physiologically‐based pharmacokinetic modelling approach
por: Schaller, Stephan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6dksihuu7cuvlm3op7smnbo4rj